Lawyers and Settlements
Advertisement
Home Page >> Legal News Articles >> Drugs/Medical

Legal News Articles - Drugs/Medical

The Watchdog Group that Rang the Bell on Anti-acid Meds

The Watchdog Group that Rang the Bell on Anti-acid Meds March 12, 2017. By Brenda Craig.
Washington, DC The Washington DC based watchdog group, Public Citizen, was among the first to start ringing the warning bell. In 2011 Public Citizen demanded that the FDA warn patients and doctors that the use of the popular prescription acid-reducing drugs came with serious health risks.
Read [ The Watchdog Group that Rang the Bell on Anti-acid Meds ]

Missouri Jury Finds in Favor of Johnson & Johnson on Talcum Powder Case

Missouri Jury Finds in Favor of Johnson & Johnson on Talcum Powder Case March 10, 2017. By Deb Hipp.
St. Louis, MO: Johnson & Johnson (J & J) won its first jury verdict out of four recent Missouri talcum powder cancer lawsuits to go to trial.
Read [ Missouri Jury Finds in Favor of Johnson & Johnson on Talcum Powder Case ]

Failed INRatio Device Fast-Tracked to Market

Failed INRatio Device Fast-Tracked to Market March 10, 2017. By Gordon Gibb.
San Diego, CA: A new Alere lawsuit filed earlier this month in San Diego asserts that the allegedly failed Alere INRatio measuring device was approved through the issuance of a 510(k) Clearance by the US Food and Drug Administration (FDA). The problematic measuring system, comprised of test strips and a measuring device, were subject to an FDA-sanctioned Alere recall in 2014. Lawsuits are continuing to roll in.
Read [ Failed INRatio Device Fast-Tracked to Market ]

Monsanto-Gate: Leaked Roundup Cancer Report

Monsanto-Gate: Leaked Roundup Cancer Report March 9, 2017. By Jane Mundy.
Washington, DC: The latest news regarding Roundup and its link to cancer doesn’t look good for Monsanto or the Environmental Protection Agency (EPA). Jess Rowland, the former Deputy Director of the EPA, may have played a major role in a cover-up to hide evidence of the possible cancer-causing glyphosate in Monsanto`s Roundup.
Read [ Monsanto-Gate: Leaked Roundup Cancer Report ]

Invokana Lawsuits Will Remain in Federal Court In Philadelphia

Invokana Lawsuits Will Remain in Federal Court In Philadelphia March 8, 2017. By Gordon Gibb.
Philadelphia, PA: A series of complex legal arguments and maneuvering with regard to jurisdictional issues may have served to briefly divert attention away from Invokana adverse events. However, plaintiffs are nonetheless steeled in their resolve to pursue compensation amidst allegations over Invokana linked with cardiovascular injuries and kidney failure.
Read [ Invokana Lawsuits Will Remain in Federal Court In Philadelphia ]

Hoping for a Hassle-Free Hip Implant a Roll of the Dice

Hoping for a Hassle-Free Hip Implant a Roll of the Dice March 7, 2017. By Gordon Gibb.
Washington, DC: Much has been written in recent years about hip implant replacement failure and the perfect storm borne from an aging population (the leading edge of Baby Boomers are entering their retirement years), and a medical device manufacturing industry rushing new designs to market bereft of adequate real-world testing through a legal FDA loophole. Coupled with the Trump Administration’s overtures that the US Food and Drug Administration is too tightly-regulated now, the die is cast for a potentially troubling future for patients assigned medical devices such as artificial hips.
Read [ Hoping for a Hassle-Free Hip Implant a Roll of the Dice ]

Number of Pending Risperdal Lawsuits Grows to 18,500 Cases

Number of Pending Risperdal Lawsuits Grows to 18,500 Cases March 7, 2017. By Deb Hipp.
New Brunswick, NJ:There are now 18,500 Risperdal lawsuits pending against Johnson & Johnson (J & J) and its subsidiary Janssen Pharmaceuticals in the US and Canada, according to Johnson & Johnson's most recent annual report.
Read [ Number of Pending Risperdal Lawsuits Grows to 18,500 Cases ]

Revenues Drop While Lawsuits Rise over Benicar for Daiichi Sankyo

Revenues Drop While Lawsuits Rise over Benicar for Daiichi Sankyo March 6, 2017. By Gordon Gibb.
Parsippany, NJ: This could evolve to a compelling year for Japanese-based pharmaceutical giant Daiichi Sankyo following the expiry of its patent exclusivity for Benicar last year and a corresponding drop in revenue for a product characterized as its global mainstay. As generics for olmesartan (Benicar) continue to gain market share in 2017, coupled with a growing number of Benicar lawsuits which number around 1,700 and climbing, industry watchers will be monitoring Daiichi in the coming months and years to see how the corporation responds, and what effect that may have on consumers.
Read [ Revenues Drop While Lawsuits Rise over Benicar for Daiichi Sankyo ]

Fighting Back Against the High Cost of Insulin

Fighting Back Against the High Cost of Insulin March 5, 2017. By Brenda Craig.
Seattle, WA It’s almost a century since two Canadian researchers discovered insulin could save the lives of diabetics. They believed that no one should profit from their remarkable discovery and sold the patent to the University of Toronto for $1. Changes to the production of insulin and expiring patents have changed all that. Today, insulin is big business.
Read [ Fighting Back Against the High Cost of Insulin ]

Abilify Makes Headlines

Abilify Makes Headlines March 4, 2017. By Jane Mundy.
Miami Beach, FL: A former arms dealer who made the news ten years ago and again last year when the film “War Dogs” was released is making headlines again, this time claiming that Abilify caused his compulsive behaviors.
Read [ Abilify Makes Headlines ]

Page: 1  -  6  7  8  9  10  11  12  -  10»  -  100»  -  123   Next»